Last reviewed · How we verify

NCT05003908

Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for Diabetes

Terminated Phase 1 Last updated 8 April 2025
What this trial tests

Phase 1 trial testing AlloRx in Diabetes in 2 participants. Terminated before completion.

Timeline
6 November 2021
Primary endpoint
4 April 2025
4 April 2025

Quick facts

Lead sponsorThe Foundation for Orthopaedics and Regenerative Medicine
PhasePhase 1
StatusTerminated
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment2
Start date6 November 2021
Primary completion4 April 2025
Estimated completion4 April 2025
Sites2 locations across Argentina, Antigua and Barbuda

Drugs / interventions tested

Conditions studied

Sponsor

The Foundation for Orthopaedics and Regenerative Medicine

Who can join

Eligibility, any sex, with Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This trial will study the safety and efficacy of intravenous infusion of cultured allogeneic adult umbilical cord derived mesenchymal stem cells for the treatment of Diabetes

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of AlloRx

Trials testing the same drug.

Other recruiting trials for Diabetes

Currently open trials in the same condition.

Other The Foundation for Orthopaedics and Regenerative Medicine trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05003908.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing